OncoGenexTM (OGXI) is a leader in developing novel therapeutics to target mechanisms of treatment resistance in cancer

  • Uniquely focused on cancer treatment resistance
  • Committed to the development and commercialization of first-in-class, innovative therapies that target important mechanisms of cancer treatment resistance and that have the potential to redefine treatment outcomes for patients with a variety of cancers
  • Robust pipeline across multiple indications, including three Phase 3 trials and multiple ongoing and planned Phase 2 trials

Learn more at www.oncogenex.com